Multiple etiologies of axonal sensory motor polyneuropathy in a renal transplant recipient: a case report by Etemadi, Jalal et al.
CASE REPORT Open Access
Multiple etiologies of axonal sensory motor
polyneuropathy in a renal transplant recipient: a
case report
Jalal Etemadi
1, Mohammadali M Shoja
2, Kamyar Ghabili
3, Mahnaz Talebi
4, Hossein Namdar
5 and Reshad Mirnour
2*
Abstract
Introduction: Neurological complications leading to morbidity and mortality are not frequent in renal transplant
recipients. Here, we report a renal transplant recipient who presented with diminished strength in his limbs
probably due to multiple etiologies of axonal sensorimotor polyneuropathy, which resolved with intravenous
immunoglobulin.
Case presentation: A 49-year-old Iranian male renal transplant recipient with previous history of autosomal
dominant polycystic kidney disease presented with diminished strength in his limbs one month after surgery. Our
patient was on cyclosporine A, mycophenolate mofetil and prednisone. Although a detected hypophosphatemia
was corrected with supplemental phosphate, the loss of strength was still slowly progressive and diffuse muscular
atrophy was remarkable in his trunk, upper limb and pelvic girdle. Meanwhile, his cranial nerves were intact. Post-
transplant diabetes mellitus was diagnosed and insulin therapy was initiated. In addition, as a high serum
cyclosporine level was detected, the dose of cyclosporine was reduced. Our patient was also put on intravenous
ganciclovir due to positive serum cytomegalovirus immunoglobulin M antibody. Despite the reduction of oral
cyclosporine dose along with medical therapy for the cytomegalovirus infection and diabetes mellitus, his muscular
weakness and atrophy did not improve. One week after administration of intravenous immunoglobulin, a
significant improvement was noted in his muscular weakness.
Conclusion: A remarkable response to intravenous immunoglobulin is compatible with an immunological basis for
the present condition (post-transplant polyneuropathy). In cases of post-transplant polyneuropathy with a high
clinical suspicion of immunological origin, administration of intravenous immunoglobulin may be recommended.
Introduction
Widespread and symmetric dysfunction of peripheral
nerves, known as polyneuropathy, may follow a number
of medical conditions (such as diabetes mellitus and
nutritional deficiency), toxic exposures (drug or environ-
mental) and infectious agents (for example, cytomegalo-
virus (CMV) infection) [1]. Neurological complications
such as polyneuropathies leading to morbidity and mor-
tality are not frequent in renal transplant recipients
[2,3]. Here, we report a renal transplant recipient who
presented with diminished strength in his limbs, prob-
ably due to multiple etiologies of axonal sensorimotor
polyneuropathy, which resolved with intravenous immu-
noglobulin (IVIG).
Case report
A 49-year-old male Iranian patient underwent living
unrelated renal transplantation after two years of hemo-
dialysis. The cause of his renal failure was autosomal
dominant polycystic kidney disease. Both donor and
recipient were seronegative for CMV. The initial post-
operative period was uneventful and our patient was dis-
charged on a regimen of cyclosporine A, mycophenolate
mofetil, prednisone, isoniazid and vitamin B6 (pyridox-
ine). One month later, he noticed diminished strength
in his arms and legs. At that time, laboratory tests
revealed hypophosphatemia. Therefore, supplemental
phosphate was started. However, his loss of strength
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u n a b l et og e tu pf r o mac h a i ra n dl i f th i sa r m so v e rh i s
head. Neurologic examinations revealed diffuse muscular
atrophy in his trunk, shoulders, upper limbs, thenar
eminence and pelvic girdle. His deep tendon reflexes
were symmetrically diminished. The muscle force grad-
ing was 3/5 in his proximal upper limbs, 4/5 in his distal
upper limbs, 2/5 in his proximal lower limbs and 4/5 in
his distal lower limbs. Sensory examinations were nor-
mal and his cranial nerves were intact.
Laboratory tests revealed hemoglobin, 13.9 g/dL; pla-
telet count, 77 × 10
3/mm
3; creatinine, 1.2 mg/dL; urea,
25 mg/dL; sodium, 137 mmol/L; potassium, 4.8 mmol/
L; calcium, 9 mg/dL; phosphorus, 2.4 mg/dL; serum
parathyroid hormone, 180 pg/mL (normal range, 17.3 to
72.9 pg/mL); aldolase, 3 U/mL (normal range: 0 to 7.6
U/mL); creatine phosphokinase, 41 IU/L (normal range:
24 to 170 IU/L); and lactate dehydrogenase, 1053 IU/L
(normal range up to 480 IU/L). Moreover, his blood glu-
cose level was elevated (400 mg/dL) and urine analysis
showed glucosuria (3+); therefore, post-transplant dia-
betes mellitus was diagnosed and insulin therapy was
commenced. Electromyography with a nerve conduction
study revealed severe axonal dominant sensory motor
polyneuropathy. However, his serum cyclosporine level
was 872 ng/mL (normal range, 250 to 375 ng/mL);
therefore, the dose of oral cyclosporine was reduced
from 225 to 150 mg twice daily. His serum CMV immu-
noglobulin M (IgM) antibody was positive; therefore
intravenous ganciclovir (5 mg/kg/day) was administrated
[4,5]. A lumbar puncture to analyze cerebrospinal fluid
was not feasible due to thrombocytopenia.
Fifty days after the reduction of the cyclosporine dose
and medical therapy for both CMV infection and post-
transplant diabetes mellitus, our patient’s muscular atro-
phy and weakness had not improved. IVIG was com-
menced (400 mg/kg/day) for five days. One week later,
significant improvement was noted in his muscular
weakness. Figure 1 illustrates the trend of neurological
symptoms, serum cyclosporine and phosphorus levels
and treatment protocols during the post-transplant per-
iod in our patient.
Discussion
Cyclosporine toxicity may induce a wide range of neuro-
logical disorders both in the central nervous system and
peripheral nerves [6,7]. Neurological complications are
usually reversible after dose reduction or discontinuation
of the medical therapy, although there have been cases
of permanent or even fatal damage [8]. Guarino et al.
observed cyclosporine-induced motor polyneuropathy in
four out of nineteen patients after liver transplantation.
Two patients had demyelinating and axonal damage and
all the patients recovered within two months of cyclos-
porine cessation [9]. Terrovitis et al. reported cyclospor-
ine-associated axonal degenerative symmetric
polyneuropathy in a patient one month after cardiac
t r a n s p l a n t a t i o n[ 6 ] .I nt h epresent case, cyclosporine
toxicity might have contributed to the development of
subacute axonal polyneuropathy. Hence, cyclosporine-
induced polyneuropathy should be considered in
patients with neurological complications following kid-
ney transplantation.
Our patient developed diabetes mellitus two months
after the renal transplantation. Diabetes mellitus is com-
monly implicated in the development of the neuropathy.
A remarkable number of patients with non-insulin
dependent diabetes mellitus are affected by slowly
Figure 1 Trend of neurological symptoms, serum cyclosporine and phosphorus levels and treatment protocols during the post-
transplant period.
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less, since the pattern of the polyneuropathy in the pre-
sent case was both acute and reversible, diabetes
mellitus seemed not to be an etiological factor.
CMV is also commonly associated with polyneuropa-
thy [11]. Identified in 10% to 15% of patients with Guil-
lian-Barré syndrome (GBS), CMV infection is the most
common antecedent viral disease [12]. In a case report,
CMV polyneuropathy presented in two kidney trans-
plant recipients as GBS [13]. In our patient, CMV infec-
tion, clinical manifestations and electromyography and
nerve conduction study findings were all in favor of a
GBS diagnosis.
Our patient was on isoniazid as a prophylactic treat-
ment of tuberculosis; renal transplantation increases the
risk of tuberculosis infection [14]. One of the earliest
known side effects of isoniazid is peripheral neuropathy
characterized by paresthesia and weakness. All symp-
toms usually disappear following isoniazid withdrawal.
Pyridoxine can prevent the neurological side effects of
isoniazid [15]. In the presented case, symptoms disap-
peared while our patient was still on isoniazid prophy-
laxis therapy. Moreover, pyridoxine was already given to
prevent peripheral neuropathy. Thus, isoniazid-induced
neurological syndrome seems not to be the etiology of
the polyneuropathy in our patient.
Hypophosphatemia, a serum phosphate level of less
than 2.5 mg/dL [16], can cause a wide range of disor-
ders including central nervous system disorders and
peripheral neuropathy. The latter can present with are-
flexia and muscle weakness. These symptoms have
been reported in cases of hypophosphatemia [17,18].
Hypophosphatemia was detected in our patient as well.
However, the clinical presentations of polyneuropathy
did not improve following correction of this electrolyte
disturbance. As a result, the polyneuropathy does not
seem to be attributable to hypophosphatemia in our
patient.
We found the present case noteworthy as more than
one etiology can be considered for the peripheral neuro-
pathy presented in our patient. These etiologies include
cyclosporine neurotoxicity, CMV-induced polyneuropa-
thy, diabetes mellitus, isoniazid-induced neuropathy and
hypophosphatemia. Since the symptoms significantly
improved once IVIG was administered, CMV-induced
polyneuropathy or GBS seems to be the most probable
cause of muscle weakness in the present report.
Conclusion
A remarkable response to IVIG is compatible with an
immunological basis for the present condition (in other
words, post-transplant polyneuropathy). In cases of
post-transplant polyneuropathy with a high clinical sus-
picion of the immunological origin (such as CMV-
induced polyneuropathy or GBS), administration of
IVIG may be recommended.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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